Forty Seven, Inc.

www.fortyseveninc.com

With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

BIO DETECTION K9 DEVELOPS CUTTING-EDGE DETECTION FOR GRAPE VIRUS DISEASES

Bio Detection K9 | May 19, 2022

news image

Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone. To combat these insidious diseas...

Read More

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

news image

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More

Cell and Gene Therapy

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

news image

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More

Diagnostics

BIODESIX ANNOUNCES RESEARCH AGREEMENT WITH TOP US CANCER CENTER

Biodesix | June 06, 2022

news image

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More

news image

Medical

BIO DETECTION K9 DEVELOPS CUTTING-EDGE DETECTION FOR GRAPE VIRUS DISEASES

Bio Detection K9 | May 19, 2022

Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone. To combat these insidious diseas...

Read More
news image

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More
news image

Cell and Gene Therapy

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More
news image

Diagnostics

BIODESIX ANNOUNCES RESEARCH AGREEMENT WITH TOP US CANCER CENTER

Biodesix | June 06, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us